# Signals Article: Putative Target P80511 for Onchocerciasis Therapeutic Development
Background
Onchocerciasis, commonly known as river blindness, is a parasitic disease caused by the filarial worm Onchocerca volvulus, transmitted through the bites of infected blackflies. This disease is a major cause of visual impairment and blindness in endemic regions, particularly in sub-Saharan Africa. Current treatment options, primarily based on ivermectin, are limited in their ability to eliminate the adult worms and require repeated administration. There is a pressing need for novel therapeutic targets to improve treatment efficacy and patient outcomes. A putative target candidate, P80511, has emerged from recent data-mining efforts, suggesting its potential role in the pathogenesis of onchocerciasis and warranting further investigation.Data-mining rationale
The identification of P80511 as a putative target was derived from a comprehensive analysis of UniProt's reviewed human entries for "Onchocerciasis," cross-referenced against three microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate P80511 appeared in several expression-profiling studies; however, it lacks any registered Phase 1 or higher clinical program. This absence indicates an opportunity for further exploration of its therapeutic potential. Additionally, many of the GEO datasets utilized in this analysis predate the adoption of modern empirical-Bayes statistical methods, such as limma, suggesting that a re-analysis could yield more robust insights.Why prior analyses may have missed this
Prior analyses may have overlooked the significance of P80511 due to several factors. The datasets analyzed were generated using older statistical methodologies that may not have adequately controlled for multiple testing, potentially obscuring the identification of differentially expressed genes. Furthermore, the complex interactions between O. volvulus and the host immune response may have diluted the signal for specific targets in earlier studies. The absence of a clinical program for P80511 further suggests that its therapeutic potential has not been fully explored in the context of onchocerciasis.Reasoning for further validation
To validate the potential of P80511 as a therapeutic target for onchocerciasis, the following experimental approaches are recommended: 1. **Re-analyze GEO Datasets**: Utilize the limma package with Benjamini-Hochberg false discovery rate (FDR) correction set to < 0.05 to re-analyze the matched GEO datasets, which may reveal more accurate differential expression results. 2. **Validate Differentially-Expressed Genes**: Conduct quantitative PCR (qPCR) validation of the top differentially expressed genes identified in the re-analysis using an independent cohort to confirm their relevance in O. volvulus infection. 3. **Check Tissue Specificity**: Investigate the tissue specificity of P80511 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to assess its potential as a therapeutic target. 4. **Pathway Context Analysis**: Employ STRING or OmniPath databases to explore the biological pathways associated with P80511, providing context for its role in onchocerciasis pathogenesis. 5. **Assess Druggability**: If P80511 is validated as a relevant target, evaluate its druggability using databases such as DGIdb and ChEMBL to identify potential small molecules or compounds that could be developed into therapeutics.References
- UniProt: P80511
- UniProt: P05109
- GEO Datasets: GDS:200015017, GDS:200014940, GDS:200014939